Influence of sex on the development of secondary failure of genetically engineered biological drugs in bio-naive patients with psoriatic arthritis
https://doi.org/10.34680/2076-8052.2023.2(131).275-281
Abstract
Currently, the problem of psoriatic arthritis is very relevant and attracts the attention of researchers from the standpoint of studying the factors associated with all aspects of this disease, including the effectiveness of the therapy. The present study was aimed at studying the possibility of the influence of sex on the development of secondary failure of genetically engineered biological drugs in bio-naive patients with psoriatic arthritis. According to the results obtained, among patients receiving genetically engineered biological therapy, the period of development of secondary failure of the first-line genetically engineered biological drug was higher in women. The revealed pattern differs from the results obtained when comparing the survival of genetically engineered biological therapy in general in men and women with psoriatic arthritis but correlates with data on sex differences in the course and manifestations of the disease. Thus, the results of the study suggest the influence of sex on the development of secondary failure of genetically engineered biological drugs in patients with psoriatic arthritis, which necessitates further research in this direction with greater selectivity.
About the Authors
A. S. Denisenko
Yaroslav-the-Wise Novgorod State University
Russian Federation
Russian Federation
Denisenko A. S.,
Veliky Novgorod.
A. V. Ivanova
Yaroslav-the-Wise Novgorod State University
Russian Federation
Russian Federation
Ivanova A. V.,
Veliky Novgorod.
References
1. Psoriaz artropaticheskij. Psoriaticheskij artrit: klinicheskie rekomendacii: odobreno nauchno-prakticheskim Sovetom Minzdrava RF [Arthropathic psoriasis. Psoriatic arthritis: clinical guidelines]. Moscow, 2021. Available at: https://diseases.medelement.com/disease/псориатический-артрит-псориаз-артропатический-кп-рф-2021/16995 (Accessed: 24.10.2022).
2. Korotaeva T. V., Korsakova Y. L. Psoriaticheskij artrit: klassifikaciya, klinicheskaya kartina, diagnostika, lechenie [Psoriatic arthritis: classification, clinical picture, diagnosis, treatment]. Rheumatology Science and Practice. 2018. 56(1). 60-69. DOI: 10.14412/1995-4484-2018-60-69
3. Gladman D. D. Sex Effect in Psoriatic Arthritis // The Journal of Rheumatology. 2023. 50(2). 159-160. DOI: 10.3899/jrheum.220948
4. Luigi Bragazzi N., Bridgewood C., Watad A., Damiani G., McGonagle D. Sex-Based Medicine Meets Psoriatic Arthritis: Lessons Learned and to Learn // Frontiers in Immunology. 2022. 13. 849560. DOI: 10.3389/fimmu.2022.849560
5. Carretero G., Puig L., Carrascosa J. M., Ferrándiz L., Ruiz-Villaverde R., de la Cueva P., Belinchon I., Vilarrasa E., Del Rio R., Sánchez-Carazo J. L., López-Ferrer A., Peral F., Armesto S., Eiris N., Mitxelena J., Vilar-Alejo J., Martin M. A., Soria C. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy // Journal of Dermatological Treatment. 2018. 29(4). 334-346. DOI: 10.1080/09546634.2017.1395794.
6. Van Kuijk A. W. R., Nurmohamed M. T., Siebert S., Bergmans P., de Vlam K., Gremese E., Joven-Ibáñez B., Korotaeva T. V., Lavie F., Sharaf M., Wim Noël, Theander E., Smolen J. S., Gossec L., van der Horst-Bruinsma I. E. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data // Rheumatology (Oxford). 2023. Kead089. DOI: 10.1093/rheumatology/kead089
7.
Review
For citations:
Denisenko A.S., Ivanova A.V. Influence of sex on the development of secondary failure of genetically engineered biological drugs in bio-naive patients with psoriatic arthritis. Title in english. 2023;(2(131)):275-281. (In Russ.) https://doi.org/10.34680/2076-8052.2023.2(131).275-281
Views:
68
Email this article 